On May 6, 2022 InterVenn Biosciences, the leader in applied glycoproteomics, reported that it will present new clinical data detailing the success of its novel approach to liquid biopsy testing in multiple cancer indications at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting (Press release, InterVenn Biosciences, MAY 6, 2022, View Source [SID1234613802]). The meeting will take place from June 3 to June 7 at McCormick Place in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

InterVenn will present two posters and five online publications highlighting data that demonstrate clinically relevant applications of its glycoproteomics-based biomarker signatures in a variety of cancers, including malignant melanoma, ovarian cancer, colorectal cancer, non-small-cell lung carcinoma, and bone and soft tissue sarcoma.

"We look forward to sharing our data at ASCO (Free ASCO Whitepaper) 2022 further validating the power of InterVenn’s pioneering glycoproteomic biomarker signatures to transform clinical care in cancer," said InterVenn CEO Aldo Carrascoso. "As a mission-driven company, InterVenn is building a robust pipeline of accessible, clinically validated and powerful tests, with the aim of detecting cancer earlier, treating it more effectively, and saving lives."

The InterVenn approach addresses many of the common challenges associated with liquid biopsy analysis by industrializing the process of glycoproteomics-based blood testing at high accuracy with fast turnaround times. Unlike other non-invasive methods, it does not depend on detecting material shed by tumors, and therefore allows the detection of very early-stage, potentially curable tumors that are commonly missed by other technologies. It also requires a significantly lower blood sample volume than most other analytical platforms.

InterVenn Presentations at ASCO (Free ASCO Whitepaper) 2022

Poster Presentations:

Title: "Serum glycoproteomic signatures predict overall survival in bone and soft tissue sarcoma patients treated with immune checkpoint inhibitor therapy"
Presenter: D. Serie, C. Pickering, R. Rice, M. Wong, H. Huang, M. Kansara, DM. Thomas, and K. Lindpaintner

Title: "Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment benefit in metastatic malignant melanoma"
Presenter: A. Mitchell, C. Pickering, G. Xu, K. Vigal, B. Axenfeld, R. Rice, X. Cong, D. Frederick, W. A. Michaud, G. Boland, D. Serie, and K. Lindpaintner

Online Publications:

Title: "Glycoproteomics as a powerful liquid biopsy based screening tool for NSCLC"
Author: C. Pickering, G. Xu, R. Rice, A. Castellanos, R. Bhadra, L. Brcic, J. Lindenmann, F.M. Smolle-Juettner, K. Lindpaintner, D. Serie, and A. Mitchell

Title: "Clinicians’ perspectives on use of immune checkpoint inhibitors and related biomarkers for solid tumors"
Author: K. Moser, M. Soto, D. Geba, P. Allen, and K. Lindpaintner

Title: "Identifying potential glycoproteomic biomarkers for diagnosis of colorectal cancer"
Author: K. Desai, G. Xu, R. Rice, A. Castellanos, D. Serie, A. Mitchell, and K. Lindpaintner

Title: "Liquid-biopsy derived glycoproteomic profiling as a novel means for non-invasive diagnosis of ovarian cancer"
Author: C. Pickering, P. Aiyetan, G. Xu, R. Rice, P. Ramachandran, K. Moser, D. Serie, and K. Lindpaintner

Title: "Predicting Breast Cancer in Women using Liquid Biopsy-Derived Glycoproteomic Marker"
Author: A. Mitchell, A. Srinivasan, G. Xu, R. Rice, A. Castellanos, R. Bhadra, D. Serie, X. Cong, and K. Lindpaintner

On May 6, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May (Press release, Ambrx, MAY 6, 2022, View Source [SID1234613801]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM Pacific Time / 3:00 PM Eastern Time.

H.C. Wainwright Global Investment Conference. Dr. Tian will conduct a pre-recorded presentation that will be available on-demand on Tuesday, May 24 at 4:00 AM Pacific Time / 7:00 AM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company’s website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.

On May 6, 2022 Palisade Bio, Inc. (Nasdaq: PALI) (the "Company" or "Palisade Bio"), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, reported that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share (Press release, Seneca Biopharma, MAY 6, 2022, View Source [SID1234613792]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

The closings of the sale of the securities in the financing is expected to occur on or about May 10, 2022, subject to the satisfaction of customary closing conditions. Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes, including the development of the Company’s lead product candidate LB1148.

The Company also agreed to issue to the investors in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 3,646,690 shares of its common stock. The warrants have an exercise price of $0.7105 per share of common stock, will be exercisable 6 months after the date of issuance, and will expire five and a half years following the initial issuance date.

The shares of common stock (but not the warrants or the shares of common stock underlying such warrants) offered in the registered direct offering are being offered and sold by the Company pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-263705), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on April 26, 2022. The offering of the shares of common stock in the registered direct transaction are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at View Source Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting Ladenburg Thalmann & Co. Inc. at Attn: Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, NY 10019 or by e-mail at [email protected]..

The warrants (and the shares of common stock underlying such warrants) are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and/or Regulation D promulgated thereunder, and such securities have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Palisade Bio has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon the exercise of the warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

On May 6, 2022 Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinicalstage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported to a Capital Markets Day for analysts and investors in Oslo, Norway, on May 12, from 2.00-4.00 p.m. CET / 8.00-10.00 a.m. ET (Press release, Nykode Therapeutics, MAY 6, 2022, View Source [SID1234613790]). The event will be hosted both with the possibility for physical attendance and as a live webcast from Nykode’s facilities in Oslo, Norway, and will take place in English.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Capital Markets Day will feature Nykode’s Executive Management Team who will provide updates on Nykode’s business, pipeline, and innovations. All sessions are webcasted live, and a replay will be made available on the investor section of nykode.com. The presentation material from the Capital Markets Day will also be available on the day from 8.00 a.m. CET on the investor section of nykode.com.

Topics of the Capital Markets Day will include:
• Nykode’s business status and journey
• Pipeline update – Overview of Nykode’s product candidate pipeline and clinical experience
• Research update – Deep dive into Nykode’s research and the ongoing technology projects
• Capital market strategy update, including potential uplisting to the main market of Oslo Stock
Exchange (Oslo Børs)
Physical attendance requires registration. To register for the physical event, please send an email to
[email protected] before May 11 at 3.00 p.m. CET.

May 06, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), has expired in connection with the Company’s previously announced exclusive worldwide collaboration agreement with Sanofi (Press release, IGM Biosciences, MAY 6, 2022, View Source [SID1234613787]). In connection with the closing of the collaboration agreement, Sanofi will pay IGM a $150 million upfront payment. The collaboration is for the creation, development, manufacture, and commercialization of IgM antibody agonists against three oncology targets and three immunology/inflammation targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce today the official start of our exciting collaboration with the talented and dedicated team at Sanofi, having now closed the transaction," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "We look forward to building on our longstanding relationship with Sanofi, a global leader in the development and commercialization of innovative therapies, and to accelerating the development of our IgM antibody platform across multiple areas of high unmet need beyond our current pipeline efforts."

In addition to the $150 million upfront payment, IGM is eligible to receive potentially over $6 billion in aggregate development, regulatory and commercial milestones, as well as a 50:50 profit share in certain major market countries and tiered royalties on net sales in the rest of world for oncology targets, and tiered royalties on global net sales for autoimmune/inflammation targets.